Inform and educate.
AccessMonitor™ - Asia-Pacific |
The AccessMonitor™ - Asia-Pacific Edition curates the top news and analyses on topics impacting pricing, reimbursement and market access of innovative health technologies in key Asia-Pacific (APAC) markets. It is an essential reading list for those who want to stay informed and educated on key market access development in the region. Expect us every other Monday morning US ET!
The APAC region is the world’s second largest pharmaceutical market and accounts for 30% of all global pharmaceutical spending, a figure that will increase as the region’s healthcare burden rises, especially for chronic disease treatments (e.g., cancer, diabetes, rare diseases, dementia therapies).
Within APAC, China and Japan are the two powerhouse economies and prescription markets, together accounting for one-fifth of global pharma spending. Moody’s Investor Services predict China’s domestic regulatory reforms will support the faster roll-out of innovative drugs. This will benefit a broad range of specialty pharma companies in particular, oncology focused players.
Given its vast market potential, the region, however, is one of the most complex when it comes to market access. Unlike in developed economies in Europe and in the US, where market access is chiefly concerned with pricing and with satisfying local conditions, such as obtaining the appropriate ICER threshold in the UK, in Asia-Pacific, the challenge is more complex due to the region’s economic and regulatory heterogeneity. The complexity means that life sciences firms need to define market access in a broader way that considers regulatory, pricing, reimbursement, HTA and local healthcare infrastructure constraints holistically.
Our AccessMonitor™ - Asia-Pacific Edition is designed to give you the best sources to understand these in your inbox every other Monday morning while saving you valuable time.
Within APAC, China and Japan are the two powerhouse economies and prescription markets, together accounting for one-fifth of global pharma spending. Moody’s Investor Services predict China’s domestic regulatory reforms will support the faster roll-out of innovative drugs. This will benefit a broad range of specialty pharma companies in particular, oncology focused players.
Given its vast market potential, the region, however, is one of the most complex when it comes to market access. Unlike in developed economies in Europe and in the US, where market access is chiefly concerned with pricing and with satisfying local conditions, such as obtaining the appropriate ICER threshold in the UK, in Asia-Pacific, the challenge is more complex due to the region’s economic and regulatory heterogeneity. The complexity means that life sciences firms need to define market access in a broader way that considers regulatory, pricing, reimbursement, HTA and local healthcare infrastructure constraints holistically.
Our AccessMonitor™ - Asia-Pacific Edition is designed to give you the best sources to understand these in your inbox every other Monday morning while saving you valuable time.
eCourses
Our self-paced eCourses focus on building a practical understanding of clinical and economic evidence used to inform health care decision-making in a global context.